This regulation defines the purpose, the operational processes, and the organization of the registry BEAT-SHOCK (Basel Evaluation of Acute Therapy in cardiogenic SHOCK). It describes the requirements for collecting, storing, processing, managing and sharing health-related registry data.
Patients admitted with cardiogenic shock to the University hospital Basel (diagnosis at the time of admission) or development of cardiogenic shock during the hospital stay
Age ≥18 years
Provision of written ICF
Clinical diagnosis of cardiogenic shock.
Age <18 years
Refusal to provide informed consent by the patient or their legally authorized representative
Adult patients who are treated at the University Hospital Basel and are diagnosed with cardiogenic shock, irrespective of underlying etiology or therapeutic strategy. The registry includes a wide range of cardiogenic shock etiologies, including: * Myocardial infarction (MI) * Fulminant myocarditis * Acute decompensated heart failure * Severe valvular disease * Post-cardiotomy or perioperative cardiogenic shock
Cohort
Prospective
no internvention
Other interventionThis is a health data registry.
In-Hospital all-cause mortality occurring before discharge from the participating study centre
In-hospital all-cause mortality is defined as death occurring before discharge from the participating study centre. Deaths occurring after transfer to an external hospital are not counted as in-hospital deaths, but are captured through follow-up for 30-day and 90-day mortality.
30-day and 90-day all-cause Mortality
30-day and 90-day all-cause mortality occuring after discharge from the participating study centre.
Need for organ support at any time during hospitalization
The need for organ support at any time during hospitalization (including renal replacement therapy, mechanical circulation support irrespective of type, and vasoactive or inotropic therapy)
Acute kidney injury (AKI) within 36 hours after index diagnosis of cardiogenic shock/index presentation
Occurence of AKI (defined as an increase in serum creatinine of at least 26 µmol/L (0.3 mg/dL)
Click on the lead sponsor to view all of their trials.
